Clinical Study Comparing the Efficacy and Safety of IDP-126 Gel in the Treatment of Acne Vulgaris

ClinicalTrials.gov ID: NCT04214639

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT04214639. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 13, 2026, 6:41 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 3, Multicenter, Randomized, Double-Blind, Vehicle Controlled, Parallel-Group, Clinical Study Comparing the Efficacy and Safety of IDP-126 Gel in the Treatment of Acne Vulgaris

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This is a multicenter, randomized, double-blind, vehicle-controlled, 12-week study designed to assess the safety, tolerability, and efficacy of IDP-126 Gel in comparison IDP-126 Vehicle Gel at Weeks 2, 4, 8, and 12.

Study identification

NCT ID: NCT04214639
Recruitment status: Completed
Study type: Interventional
Phase: Phase 3
Lead sponsor: Bausch Health Americas, Inc.; Industry
Enrollment: 183 participants

Conditions and interventions

Conditions

Acne Vulgaris

Interventions

IDP-126 Gel Drug
IDP-126 Vehicle Gel Drug

Drug

Eligibility (public fields only)

Age range: 9 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Jan 17, 2020 (Actual)
Primary completion: Jan 18, 2021 (Actual)
Completion: Jan 18, 2021 (Actual)
Last update posted: Feb 1, 2024

2020 – 2021

United States locations

U.S. sites: 11
U.S. states: 9
U.S. cities: 11

Facility	City	State	ZIP	Site status
Bausch Site 110	Bryant	Arkansas	72022	—
Bausch Site 104	Fremont	California	94538	—
Bausch Site 109	Denver	Colorado	80220	—
Bausch Site 102	Boynton Beach	Florida	33463	—
Bausch Site 111	North Miami Beach	Florida	33162	—
Bausch Site 106	Sanford	Florida	32771	—
Bausch Site 103	Las Vegas	Nevada	89148	—
Bausch Site 114	New York	New York	10075	—
Bausch Site 105	High Point	North Carolina	27262	—
Bausch Site 107	Nashville	Tennessee	37215	—
Bausch Site 108	Pflugerville	Texas	78660	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 2 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT04214639, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Feb 1, 2024 · Synced Nov 13, 2026